These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22128433)

  • 41. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review.
    Sparrow SS; Robinson S; Bolam S; Bruce C; Danks A; Everett D; Fulcher S; Hill RE; Palmer H; Scott EW; Chapman KL
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):222-9. PubMed ID: 21855593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The study pathologist's role in GLP studies: a regulator's perspective.
    Seaton M
    Toxicol Pathol; 2014 Jan; 42(1):285. PubMed ID: 24178580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation.
    Creton S; Saghir SA; Bartels MJ; Billington R; Bus JS; Davies W; Dent MP; Hawksworth GM; Parry S; Travis KZ
    Regul Toxicol Pharmacol; 2012 Mar; 62(2):241-7. PubMed ID: 22198561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory forum opinion piece: obligatory microscopic examination of intermediate dose groups in non-rodent toxicity studies--is it necessary?
    Weddle DL; Mahrt CR; Schmidt SP
    Toxicol Pathol; 2012 Jul; 40(5):826-9. PubMed ID: 22421750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of toxicokinetic data in preclinical safety assessment: a toxicologic pathologist perspective.
    Ploemen JP; Kramer H; Krajnc EI; Martin I
    Toxicol Pathol; 2007 Oct; 35(6):836-9. PubMed ID: 17943658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Providing toxicokinetic support for reproductive toxicology studies in pharmaceutical development.
    Schwartz S
    Arch Toxicol; 2001 Sep; 75(7):381-7. PubMed ID: 11693177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
    Sewell F; Chapman K; Baldrick P; Brewster D; Broadmeadow A; Brown P; Burns-Naas LA; Clarke J; Constan A; Couch J; Czupalla O; Danks A; DeGeorge J; de Haan L; Hettinger K; Hill M; Festag M; Jacobs A; Jacobson-Kram D; Kopytek S; Lorenz H; Moesgaard SG; Moore E; Pasanen M; Perry R; Ragan I; Robinson S; Schmitt PM; Short B; Lima BS; Smith D; Sparrow S; van Bekkum Y; Jones D
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):413-29. PubMed ID: 25078890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory forum opinion piece*: reversibility groups: the "hows" and "how-nots".
    Ochoa R
    Toxicol Pathol; 2013; 41(3):552-3. PubMed ID: 22821368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.
    Walker DK
    Br J Clin Pharmacol; 2004 Dec; 58(6):601-8. PubMed ID: 15563358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose.
    Spurling NW; Carey PF
    Hum Exp Toxicol; 1992 Nov; 11(6):449-57. PubMed ID: 1361132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor models: assessing toxicity in efficacy studies.
    Arp LH
    Toxicol Pathol; 1999; 27(1):121-2. PubMed ID: 10367686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The application of toxicokinetic data to dosage selection in toxicology studies.
    Morgan DG; Kelvin AS; Kinter LB; Fish CJ; Kerns WD; Rhodes G
    Toxicol Pathol; 1994; 22(2):112-23. PubMed ID: 7973359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.
    Dahlem AM; Allerheiligen SR; Vodicnik MJ
    Toxicol Pathol; 1995; 23(2):170-8. PubMed ID: 7569672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advantages of toxicokinetics in new drug development.
    Horii I
    Toxicol Lett; 1998 Dec; 102-103():657-64. PubMed ID: 10022331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The integration of investigative toxicology in the drug discovery process.
    Dean JH; Olson HM
    Biol Cell; 1993; 77(1):3-8. PubMed ID: 8518743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of transcriptome analysis in pre-clinical toxicology.
    Searfoss GH; Ryan TP; Jolly RA
    Curr Mol Med; 2005 Feb; 5(1):53-64. PubMed ID: 15720270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alternatives to statistical decision trees in regulatory (eco-)toxicological bioassays.
    Kluxen FM; Hothorn LA
    Arch Toxicol; 2020 Apr; 94(4):1135-1149. PubMed ID: 32193567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [An evaluation of non-clinical animal data from the point of view of a clinical pharmacologist].
    Uchida E
    Nihon Yakurigaku Zasshi; 1999 Jan; 113(1):47-53. PubMed ID: 10096105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The rationale for using logarithmic transformation of concentration data in toxicokinetic studies.
    Igarashi T
    J Toxicol Sci; 1995 Feb; 20(1):67-72. PubMed ID: 7595977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A call for fuller reporting of toxicity test data.
    Meyer JN; Francisco AB
    Integr Environ Assess Manag; 2013 Apr; 9(2):347-8. PubMed ID: 23529809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.